Amylyx Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.
Amylyx Pharmaceuticals' co-founder Joshua Cohen sold $950k worth of stock at $32.16 per share, reducing his holding by 0.9%. This was the largest insider sale in the past year, occurring below the current price of $33.15. Insiders have sold more shares than bought over the past year, with total insider ownership at 6.2% of the company.
Amylyx Pharmaceuticals (AMLX) shares declined after a Morgan Stanley event, retreating from 52-week highs. Investors reassess valuation due to manufacturing commitments and capital needs for a 2027 drug launch. Recent rally and public offering raised scrutiny over funding strategy and execution risk. Long-term prospects depend on avexitide's success, but cash burn and reliance on equity offerings pose challenges.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning AMLX (Amylyx Pharmaceuticals, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent AMLX coverage spans insider activity, financial news and market movers.
In the last 30 days, AMLX insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($2.9M). The most active reporter was Mazzariello Gina, Chief Legal Officer, with 2 filings.
The dilution from the large equity raise likely pressures the stock lower in the short term.
Amylyx Pharmaceuticals' co-founder Joshua Cohen sold $950k worth of stock at $32.16 per share, reducing his holding by 0.9%. This was the largest insider sale in the past year, occurring below the current price of $33.15. Insiders have sold more shares than bought over the past year, with total insider ownership at 6.2% of the company.
Negative price pressure as investors sell on funding worries.
Minor insider sell likely has limited price impact.
Insider sale may signal CFO's view on near‑term valuation, potentially pressuring AMLX stock modestly.
AlphAI scores every news story that mentions AMLX with an AI model for sentiment and relevance, and aggregates insider trades from Amylyx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.
2 min readAmylyx Pharmaceuticals' co-founder Joshua Cohen sold $950k worth of stock at $32.16 per share, reducing his holding by 0.9%. This was the largest insider sale in the past year, occurring below the current price of $33.15. Insiders have sold more shares than bought over the past year, with total insider ownership at 6.2% of the company.
1 min readAmylyx Pharmaceuticals (AMLX) shares declined after a Morgan Stanley event, retreating from 52-week highs. Investors reassess valuation due to manufacturing commitments and capital needs for a 2027 drug launch. Recent rally and public offering raised scrutiny over funding strategy and execution risk. Long-term prospects depend on avexitide's success, but cash burn and reliance on equity offerings pose challenges.
2 min readBedrosian Camille L (Chief Medical Officer) sold 10,028 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.40 ($32.21–$33.09, $0.32M total) across 2 trades on 2026-09-10.
1 min readFRATES JAMES M (Chief Financial Officer) sold 10,810 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.36 ($32.27–$33.23, $0.35M total) across 2 trades on 2026-09-10.
1 min readMazzariello Gina (Chief Legal Officer) sold 9,536 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.46 ($32.46–$33.34, $0.31M total) across 2 trades on 2026-09-10.
1 min readKlee Justin B. (Co-Chief Executive Officer) sold 30,464 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.18 ($32.13–$33.16, $0.98M total) across 2 trades on 2026-09-10.
1 min readCohen Joshua B (Co-Chief Executive Officer) sold 30,464 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.19 ($32.16–$33.15, $0.98M total) across 2 trades on 2026-09-10.
1 min readAmylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.
1 min readAmylyx Pharmaceuticals (AMLX) officer Gina Mazzariello plans to sell 21,284 shares to cover tax withholding obligations tied to vested performance-based stock units. The sale is scheduled for September 10, 2026, and is automatic, not discretionary. Mazzariello previously sold 30,000 shares in the prior three months.
1 min read
